Shuttle Pharmaceuticals Holdings Inc (SHPH) USD0.00001

Sell:$0.34Buy:$0.42$0.02 (4.81%)

Prices delayed by at least 15 minutes
Sell:$0.34
Buy:$0.42
Change:$0.02 (4.81%)
Prices delayed by at least 15 minutes
Sell:$0.34
Buy:$0.42
Change:$0.02 (4.81%)
Prices delayed by at least 15 minutes

Company Information

About this company

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.

Key people

Anatoly Dritschilo
Chairman of the Board, Chief Scientific Officer
Peter Dritschilo
President, Chief Operating Officer
Christopher R. Cooper
Interim Chief Executive Officer
Timothy J. Lorber
Chief Financial Officer
Tyvin A. Rich
Chief Medical Officer, Chief Clinical Officer
Oleh Nabyt
Director
George Scorsis
Director
Joseph Tung
Director
Steven Richards
Independent Director
Click to see more

Key facts

  • EPIC
    SHPH
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8256933024
  • Market cap
    $2.43m
  • Employees
    9
  • Shares in issue
    6.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.